EUVIMEDEUVIMED entdecken
Open Access

Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States

Dana Weisenfeld iD, Fan Zhang, Laura Donlin, Anna Helena Jonsson iD, William Apruzzese iD, Debbie Campbell, Accelerating Medicines Partnership Program: RA/SLE Network, Deepak A Rao iD, Kevin Wei, V Michael Holers, Ellen Gravallese, Larry Moreland und 7 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Dana Weisenfeld und 18 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHGRI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Recent studies have uncovered diverse cell types and states in the rheumatoid arthritis (RA) synovium; however, limited data exist correlating these findings with patient‐level clinical information. Using the largest cohort to date with clinical and multicell data, we determined associations between RA clinical factors with cell types and states in the RA synovium.

Methods

The Accelerated Medicines Partnership Rheumatoid Arthritis study recruited patients with active RA who were not receiving disease‐modifying antirheumatic drugs (DMARDs) or who had an inadequate response to methotrexate (MTX) or tumor necrosis factor inhibitors. RA clinical factors were systematically collected. Biopsies were performed on an inflamed joint, and tissue were disaggregated and processed with a cellular indexing of transcriptomes and epitopes sequencing pipeline from which the following cell type percentages and cell type abundance phenotypes (CTAPs) were derived: endothelial, fibroblast, and myeloid (EFM); fibroblasts; myeloid; T and B cells; T cells and fibroblasts (TF); and T and myeloid cells. Correlations were measured between RA clinical factors, cell type percentage, and CTAPs.

Results

We studied 72 patients (mean age 57 years, 75% women, 83% seropositive, mean RA duration 6.6 years, mean Disease Activity Score‐28 C‐reactive Protein 3 [DAS28‐CRP3] score 4.8). Higher DAS28‐CRP3 correlated with a higher T cell percentage ( P < 0.01). Those receiving MTX and not a biologic DMARD (bDMARD) had a higher percentage of B cells versus those receiving no DMARDs ( P < 0.01). Most of those receiving bDMARDs were categorized as EFM (57%), whereas none were TF. No significant difference was observed across CTAPs for age, sex, RA disease duration, or DAS28‐CRP3.

Conclusion

In this comprehensive screen of clinical factors, we observed differential associations between DMARDs and cell phenotypes, suggesting that RA therapies, more than other clinical factors, may impact cell type/state in the synovium and ultimately influence response to subsequent therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansFemaleMiddle AgedMaleMethotrexateSynovial MembraneRheumatoid Factor

Substanzen

Antirheumatic AgentsMethotrexateRheumatoid Factor

Autor:innen und Institutionen

  • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • University of Colorado School of Medicine, Aurora, Colorado.
  • Weill Cornell Medicine and Hospital for Special Surgery, New York, New York.
  • Accelerated Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus Network.
  • University of Rochester Medical Center, Rochester, New York.

ORCID-Profile: Dana Weisenfeld, Anna Helena Jonsson, William Apruzzese, Deepak A Rao, Susan Goodman, Katherine P Liao

Förderung

  • NIAMS NIH HHS
  • NHGRI NIH HHS
  • NIAID NIH HHS
  • Medical Research Council
  • Arthritis National Research Foundation
  • Birmingham Biomedical Research Centre
  • Burroughs Wellcome Fund
  • Innovative Medicines Initiative

Zitieren

APA

Weisenfeld, D., Zhang, F., Donlin, L., Jonsson, A. H., Apruzzese, W., Campbell, D., Accelerating Medicines Partnership Program: RA/SLE Network, Rao, D. A., Wei, K., Holers, V. M., Gravallese, E., Moreland, L., Goodman, S., Brenner, M., Raychaudhuri, S., Filer, A., Anolik, J., Bykerk, V., & Liao, K. P. (2024). Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States. Arthritis & Rheumatology. https://doi.org/10.1002/art.42726

Vancouver

Weisenfeld D, Zhang F, Donlin L, Jonsson AH, Apruzzese W, Campbell D, et al. Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States. Arthritis & Rheumatology. 2024. doi:10.1002/art.42726

BibTeX
@article{Weisenfeld2024,
  author = {Weisenfeld, Dana and Zhang, Fan and Donlin, Laura and Jonsson, Anna Helena and Apruzzese, William and Campbell, Debbie and Accelerating Medicines Partnership Program: RA/SLE Network, Accelerating Medicines Partnership Program: RA/SLE Network and Rao, Deepak A and Wei, Kevin and Holers, V Michael and Gravallese, Ellen and Moreland, Larry and Goodman, Susan and Brenner, Michael and Raychaudhuri, Soumya and Filer, Andrew and Anolik, Jennifer and Bykerk, Vivian and Liao, Katherine P},
  title = {Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42726}
}
Kostenlos starten →